Perrigo And Sol-Gel Face Up To Duobrii Lawsuit
ANDA Filed By Perrigo In July
Collaboration partners Perrigo and Sol-Gel Technologies face legal action stemming from Perrigo’s filing of an ANDA for generic Duobrii lotion for the treatment of plaque psoriasis in adults.
You may also be interested in...
Teva Capitalizes On Patent Expiry To Launch First Perforomist Rival
Teva has added to its vast portfolio in the US by introducing the first generic version of Viatris’ Perforomist for chronic obstructive pulmonary disease, as well as a generic of Soolantra to treat rosacea.
What’s Next? Five Things To Look Out For In April
In April, four Humira (adalimumab) biosimilars are to be listed on Australia’s Pharmaceutical Benefits Scheme, while first-quarter financial reports will hit the market.
Perrigo Bolsters US Generics Ahead Of Separation Plans
Perrigo has expanded its agreement with Sol-Gel Technologies to cover ten products, shortly after warning that plans to separate the firm’s Prescription Pharmaceuticals US generics unit “in the short term” would likely “destroy shareholder value.”